Monday, July 31, 2017 2:04:47 PM
DVAX...$9 STOCK NOW $16 STOCK GETS AN UPGRADE TARGET $26\
***07/28 and 08/10 The biotech will find out by August 10 if the FDA approves the drug for use on hepatitis B patients. DVAX (T/$26)Dynavax hepatitis B vaccine.
The immunotherapy company is developing Heplisav as a hepatitis B vaccine treatment for adults. Heplisav could become the standard treatment for the viral liver infection, Rama said, because Dynavax's drug has an easier dosing schedule than competitor GlaxoSmithKline's Engerix-B.
https://finance.yahoo.com/news/dynavax-gets-12-1-fda-205950536.html
Shortly after 3p.m. ET, it was announced that The Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration voted 12-1 in support of FDA approval.
The vote was based solely on safety, but the panel previously supported the drug’s immunogenicity based on Phase 3 clinical trials.
Hepatitis B currently has no cure, so the medical community emphasizes immunizations to combat the condition.
Existing vaccines are delivered in three doses over six months, and only 54 percent of patients end up completing the course. Dynavax’s vaccine regimen will be more efficient and easier to see through, as it is administered in two doses over one month.
HEPLISAV-B’s Prescription Drug User Fee Act (PDUFA) date is Aug. 10, and if approved, Dynavax intends a commercial launch for early 2018.
The stock closed Thursday's session at $9.25 per share.07/27
60MINUTE
DVAX
***07/28 and 08/10 The biotech will find out by August 10 if the FDA approves the drug for use on hepatitis B patients. DVAX (T/$26)Dynavax hepatitis B vaccine.
The immunotherapy company is developing Heplisav as a hepatitis B vaccine treatment for adults. Heplisav could become the standard treatment for the viral liver infection, Rama said, because Dynavax's drug has an easier dosing schedule than competitor GlaxoSmithKline's Engerix-B.
https://finance.yahoo.com/news/dynavax-gets-12-1-fda-205950536.html
Shortly after 3p.m. ET, it was announced that The Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration voted 12-1 in support of FDA approval.
The vote was based solely on safety, but the panel previously supported the drug’s immunogenicity based on Phase 3 clinical trials.
Hepatitis B currently has no cure, so the medical community emphasizes immunizations to combat the condition.
Existing vaccines are delivered in three doses over six months, and only 54 percent of patients end up completing the course. Dynavax’s vaccine regimen will be more efficient and easier to see through, as it is administered in two doses over one month.
HEPLISAV-B’s Prescription Drug User Fee Act (PDUFA) date is Aug. 10, and if approved, Dynavax intends a commercial launch for early 2018.
The stock closed Thursday's session at $9.25 per share.07/27
60MINUTE
DVAX
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
